Results 21 to 30 of about 28,144 (206)
Pharmacokinetics and Pharmacogenetics of Apixaban [PDF]
, 2020 Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. Its main mechanism of action is through reversible inhibition of factor Xa.
M. M. Petrova +4 more
core +2 more sources
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. [PDF]
PLoS ONE, 2012 BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of ...
Soyon Lee +3 more
doaj +1 more source
PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
Рациональная фармакотерапия в кардиологии, 2015 Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation.
D. A. Sychev +6 more
doaj +3 more sources
Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: Real-world evidence of apixaban treatment in patients with chronic kidney disease remains scarce. This study aimed to compare the relative risk of stroke or systemic embolism (SE) and major bleeding between apixaban and ...
Chung-Ming Fu +6 more
doaj +1 more source
Quick reference guide to apixaban [PDF]
, 2017 Katherine Victoria Hurst, John Matthew O’Callaghan, Ashok Handa Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK Abstract: Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting ...
Handa A, O'Callaghan JM, Hurst KV
core +2 more sources
A study on indices of apixaban anticoagulation: A single-center prospective study
Journal of Pharmacological Sciences, 2018 Background: Depending on the characteristics of patients, the blood concentration of apixaban can unexpectedly increase, possibly leading to bleeding events.
Maki Komiyama +11 more
doaj +1 more source
Critical Analysis of Apixaban Dose Adjustment Criteria
Clinical and Applied Thrombosis/Hemostasis, 2021 Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE).
Anh Vu PharmD +5 more
doaj +1 more source
, 2022 Introduction Due to various limitations of warfarin use, non-vitamin K oral anticoagulants have gradually become the first choice for the prevention of ischemic stroke. This article will comprehensively and systematically evaluate the efficacy and safety
Wei Xie +6 more
core +1 more source
Frontiers in Pharmacology, 2022 Introduction: Accumulation of apixaban in plasma is a major concern in patients with chronic kidney disease (CKD). Studies that investigated plasma apixaban level in CKD patients and its association with clinically significant events are scarce.Methods ...
Chun-fung Sin +5 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real‐world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model‐based simulations helped to identify factors that affect apixaban
Frédéric Gaspar +11 more
doaj +1 more source